07:00 , Oct 31, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Cardiovascular disease; sickle cell disease (SCD) Hemopexin (HPX); toll-like receptor 4 (TLR4) Mouse studies suggest TLR4 blockade or recombinant HPX could help prevent SCD-associated acute...
07:00 , Apr 5, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Matrix metalloproteinase 14 (MMP14) Mouse studies identified an inhibitor of MMP14 dimerization that could help treat breast cancer. In mice, transplantation of breast...
07:00 , Jun 23, 2011 |  BC Innovations  |  Targets & Mechanisms

A bid to revive MMP inhibitors

Matrix metalloproteinases , or MMPs, were once viewed as obvious drug targets-extracellular proteases that are selectively upregulated and play critical functional roles in many diseases. But MMP inhibitors failed in cancer trials a decade ago...
07:00 , Oct 14, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Sepsis Hemopexin (HPX) Mouse and patient sample studies suggest that delivering the heme-binding protein HPX could help treat severe sepsis....
07:00 , Mar 19, 2007 |  BioCentury  |  Tools & Techniques

HDL's influential cargo

Researchers investigating the antiatherosclerotic properties of high-density lipoprotein unexpectedly found multiple complement-associated proteins and other proteins involved in inflammation in HDL isolated from patients with coronary artery disease. The findings, published in The Journal of...